It was recently shown that mTOR inhibitors impair homologous recombination repair and synergize with PARP inhibitors through a negative regulation of SUV39H1 in BRCA-proficient triple-negative breast cancer cell lines [31]. Here, PARP1 is linked to triple-negative breast carcinoma.